Zevra Therapeutics (NASDAQ:ZVRA) Sets New 52-Week High - Here's Why

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $13.16 and last traded at $12.79, with a volume of 1700798 shares trading hands. The stock had previously closed at $12.79.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZVRA. Wall Street Zen raised Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. HC Wainwright initiated coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price objective on the stock. Cantor Fitzgerald boosted their price target on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. Finally, Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Zevra Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Stock Down 4.7%

The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02. The firm has a market capitalization of $659.99 million, a P/E ratio of -6.35 and a beta of 1.97. The stock has a fifty day moving average price of $9.54 and a two-hundred day moving average price of $8.35.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. The business had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. During the same period in the previous year, the business earned ($0.40) EPS. Research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth $53,000. GAMMA Investing LLC lifted its holdings in shares of Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock valued at $60,000 after purchasing an additional 8,020 shares during the last quarter. Strs Ohio purchased a new stake in shares of Zevra Therapeutics during the first quarter valued at $125,000. Squarepoint Ops LLC lifted its holdings in shares of Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after purchasing an additional 4,384 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Zevra Therapeutics during the fourth quarter valued at $145,000. Institutional investors and hedge funds own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.